Oncology Venture participates at ‘Investordagen’ in Copenhagen 21st March 2017 – get your free ticket here
Oncology Venture will participate with a booth at the event at Dansk Aktionærforening Tuesday 21st March 2017 from 1.00 – 9.00 PM. Oncology Venture and Dansk aktionærforening offers investors a free ticket to the event where you can hear lectures from CEO Peter Buhl Jensen and other interesting investor presentations from the day.
If you would like to participate and learn about Oncology Venture go to – http://butik.shareholders.dk/events/1668-daf/investordagen-i-kobenhavn and click on Register at the top right. In the next picture you use discount code viponcology2017 and update the basket. Then you can pick up free tickets.
The event will be held at Scandic Copenhagen, Vester Søgade 6, 1601 Copenhagen. You can read about the investor event here: http://www.shareholders.dk/investordagen.
For further information about Oncology Venture, please contact:
Ulla Hald Buhl, COO and
Chief IR & Communications
Mobile: +45 2170 1049
uhb@oncologyventure.com
or
Peter Buhl Jensen, CEO
Mobile: +45 21 60 89 22
E-mail: pbj@oncologyventure.com
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.
Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor.